相关临床试验
224
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1388
进行中（未招募）
7
3.1%
已完成
116
51.8%
Enrolling By Invitation
1
0.5%
尚未招募
8
3.6%
招募中
40
17.9%
终止
9
4.0%
Unknown
42
18.8%
撤回
1
0.5%
暂无批准数据
- Researchers combined electrophysiology and brain imaging for the first time to map the deep brain stimulation (DBS) response network in Parkinson's disease across both space and time. - The network linking the subthalamic nucleus to frontal brain regions communicates at a fast 20–35 Hz (high beta) frequency, and its connection strength predicts individual patients' motor improvement after electrode implantation. - The findings could enable more precise, personalized DBS settings, especially for patients who have not yet benefited optimally from stimulation. - The multicenter study of fifty patients and one hundred brain hemispheres was led by the University of Cologne and published in the journal Brain.
- University of Cologne researchers discovered antibody 04_A06 that neutralizes 98.5% of over 300 HIV strains, making it one of the broadest HIV antibodies ever identified. - The antibody permanently reduced HIV viral load to undetectable levels in humanized mice, overcoming typical resistance mechanisms that limit other HIV antibodies. - Computer models predict 04_A06 could offer over 93% protection against HIV infection in clinical applications with a single administration. - The antibody's unique structure features an unusually long amino acid chain that targets highly conserved viral regions difficult for HIV to mutate.
- Researchers demonstrated that combining trametinib and rapamycin, two existing cancer drugs, extends mouse lifespan by approximately 30%, significantly more than either drug alone. - The combination therapy reduced chronic inflammation in brain and tissue while delaying cancer onset and development in aged mice. - Gene expression analysis revealed the drug combination produces novel effects beyond simple dose increases, with specific changes only occurring when both drugs are used together. - Scientists plan to optimize trametinib dosing for clinical trials, as the drug is already approved for human use and shows promise as a geroprotector.
- New data from the PROVE study reveals cefiderocol achieves better clinical outcomes when used as empiric (64.6%) or documented therapy (67.4%) compared to salvage therapy (58.2%) in serious gram-negative infections. - The European cohort analysis of 567 patients demonstrated a 65.3% overall clinical cure rate, with particularly high efficacy against Pseudomonas aeruginosa infections (73.1%) across multiple infection types. - Most patients in the study had respiratory tract infections, with over 70% showing carbapenem resistance and 55.9% requiring intensive care, suggesting cefiderocol's value in treating critically ill patients with resistant infections.
- The MATTERHORN trial demonstrated that transcatheter edge-to-edge repair (TEER) is non-inferior to surgery in treating secondary mitral regurgitation (MR) at one year. - Both TEER and surgery effectively improved MR, with a similar rate of MR grade ≤1 observed in both groups after one year, indicating comparable efficacy. - TEER showed a superior safety profile compared to surgery, with significantly fewer patients experiencing the primary safety endpoint at 30 days. - The findings suggest TEER could be a valuable alternative for high-risk patients with secondary MR, potentially influencing future treatment guidelines.
